Literature DB >> 33418848

Tau Oligomers Neurotoxicity.

Grazyna Niewiadomska1, Wiktor Niewiadomski2, Marta Steczkowska2, Anna Gasiorowska2.   

Abstract

Although the mechanisms of toxic activity of tau are not fully recognized, it is supposed that the tau toxicity is related rather not to insoluble tau aggregates but to its intermediate forms. It seems that neurofibrillar tangles (NFTs) themselves, despite being composed of toxic tau, are probably neither necessary nor sufficient for tau-induced neuronal dysfunction and toxicity. Tau oligomers (TauOs) formed during the early stages of tau aggregation are the pathological forms that play a key role in eliciting the loss of neurons and behavioral impairments in several neurodegenerative disorders called tauopathies. They can be found in tauopathic diseases, the most common of which is Alzheimer's disease (AD). Evidence of co-occurrence of b-amyloid, α-synuclein, and tau into their most toxic forms, i.e., oligomers, suggests that these species interact and influence each other's aggregation in several tauopathies. The mechanism responsible for oligomeric tau neurotoxicity is a subject of intensive investigation. In this review, we summarize the most recent literature on the damaging effect of TauOs on the stability of the genome and the function of the nucleus, energy production and mitochondrial function, cell signaling and synaptic plasticity, the microtubule assembly, neuronal cytoskeleton and axonal transport, and the effectiveness of the protein degradation system.

Entities:  

Keywords:  genome; mitochondria; neurotoxicity; protein degradation; signal transduction; synapses; tau oligomers; tauopathies

Year:  2021        PMID: 33418848      PMCID: PMC7824853          DOI: 10.3390/life11010028

Source DB:  PubMed          Journal:  Life (Basel)        ISSN: 2075-1729


  222 in total

1.  Proteasomal degradation of tau protein.

Authors:  Della C David; Robert Layfield; Louise Serpell; Yolanda Narain; Michel Goedert; Maria Grazia Spillantini
Journal:  J Neurochem       Date:  2002-10       Impact factor: 5.372

2.  Characteristics and consequences of muscarinic receptor activation by tau protein.

Authors:  Alberto Gómez-Ramos; Miguel Díaz-Hernández; Alicia Rubio; Juan Ignacio Díaz-Hernández; Maria Teresa Miras-Portugal; Jesus Avila
Journal:  Eur Neuropsychopharmacol       Date:  2009-05-07       Impact factor: 4.600

3.  FTDP-17 mutations in tau transgenic mice provoke lysosomal abnormalities and Tau filaments in forebrain.

Authors:  F Lim; F Hernández; J J Lucas; P Gómez-Ramos; M A Morán; J Avila
Journal:  Mol Cell Neurosci       Date:  2001-12       Impact factor: 4.314

Review 4.  Roles of tau protein in health and disease.

Authors:  Tong Guo; Wendy Noble; Diane P Hanger
Journal:  Acta Neuropathol       Date:  2017-04-06       Impact factor: 17.088

5.  Methylene Blue Inhibits Formation of Tau Fibrils but not of Granular Tau Oligomers: A Plausible Key to Understanding Failure of a Clinical Trial for Alzheimer's Disease.

Authors:  Yoshiyuki Soeda; Marino Saito; Sumihiro Maeda; Kohki Ishida; Akira Nakamura; Shuichi Kojima; Akihiko Takashima
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

6.  Mitochondrial DNA Manipulations Affect Tau Oligomerization.

Authors:  Ian W Weidling; Heather M Wilkins; Scott J Koppel; Lewis Hutfles; Xiaowan Wang; Anuradha Kalani; Blaise W Menta; Benjamin Ryan; Judit Perez-Ortiz; T Chris Gamblin; Russell H Swerdlow
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

Review 7.  New therapeutics beyond amyloid-β and tau for the treatment of Alzheimer's disease.

Authors:  Feng Zhang; Ru-Jia Zhong; Cheng Cheng; Song Li; Wei-Dong Le
Journal:  Acta Pharmacol Sin       Date:  2020-12-02       Impact factor: 7.169

Review 8.  Protein Quality Control by Molecular Chaperones in Neurodegeneration.

Authors:  Aaron Ciechanover; Yong Tae Kwon
Journal:  Front Neurosci       Date:  2017-04-06       Impact factor: 4.677

9.  Tau promotes neurodegeneration through global chromatin relaxation.

Authors:  Bess Frost; Martin Hemberg; Jada Lewis; Mel B Feany
Journal:  Nat Neurosci       Date:  2014-01-26       Impact factor: 24.884

10.  Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial.

Authors:  Gordon K Wilcock; Serge Gauthier; Giovanni B Frisoni; Jianping Jia; Jiri H Hardlund; Hans J Moebius; Peter Bentham; Karin A Kook; Bjoern O Schelter; Damon J Wischik; Charles S Davis; Roger T Staff; Vesna Vuksanovic; Trevor Ahearn; Luc Bracoud; Kohkan Shamsi; Ken Marek; John Seibyl; Gernot Riedel; John M D Storey; Charles R Harrington; Claude M Wischik
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

View more
  5 in total

Review 1.  Deregulated mitochondrial microRNAs in Alzheimer's disease: Focus on synapse and mitochondria.

Authors:  Prashanth Gowda; P Hemachandra Reddy; Subodh Kumar
Journal:  Ageing Res Rev       Date:  2021-11-20       Impact factor: 10.895

Review 2.  Microglia: Friend and foe in tauopathy.

Authors:  Kristian F Odfalk; Kevin F Bieniek; Sarah C Hopp
Journal:  Prog Neurobiol       Date:  2022-06-14       Impact factor: 10.885

Review 3.  Tau as a Biomarker of Neurodegeneration.

Authors:  Sarah Holper; Rosie Watson; Nawaf Yassi
Journal:  Int J Mol Sci       Date:  2022-06-30       Impact factor: 6.208

Review 4.  Disease modification in Parkinsonism: obstacles and ways forward.

Authors:  M Höllerhage; M Klietz; G U Höglinger
Journal:  J Neural Transm (Vienna)       Date:  2022-06-13       Impact factor: 3.850

Review 5.  Oligomeropathies, inflammation and prion protein binding.

Authors:  Gianluigi Forloni; Pietro La Vitola; Claudia Balducci
Journal:  Front Neurosci       Date:  2022-08-23       Impact factor: 5.152

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.